Avantor Return On Tangible Equity 2018-2025 | AVTR

Avantor return on tangible equity for the quarter ending March 31, 2025 was -21.64.

  • Avantor average return on tangible equity for 2024 was -10.64, a 18.35% increase from 2023.
  • Avantor average return on tangible equity for 2023 was -8.99, a 18.42% increase from 2022.
  • Avantor average return on tangible equity for 2022 was -11.02, a 37.06% decline from 2021.

Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.

Avantor Return On Tangible Equity 2018-2025 | AVTR

  • Avantor average return on tangible equity for 2024 was -10.64, a 18.35% increase from 2023.
  • Avantor average return on tangible equity for 2023 was -8.99, a 18.42% increase from 2022.
  • Avantor average return on tangible equity for 2022 was -11.02, a 37.06% decline from 2021.

Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Related Stocks
Company NameMarket
Cap
Danaher (DHR)$139.8B
CVS Health (CVS)$80.6B
Elevance Health (ELV)$62.2B
Cencora (COR)$55B
DiDi Global (DIDIY)$25.3B
Labcorp Holdings (LH)$21.7B
Natera (NTRA)$18.9B
BioMerieux (BMXMF)$17.1B
EUROFINS SCIENT (ERFSF)$14.8B
CochLear (CHEOY)$13.3B
Solventum (SOLV)$12.6B
ICON (ICLR)$12.6B
Medpace Holdings (MEDP)$12.1B
Viatris (VTRS)$10.3B
Revvity (RVTY)$10B
Sonic Healthcare (SKHHY)$9B
HealthEquity (HQY)$7.9B
Charles River Laboratories (CRL)$7.4B
Caris Life Sciences,�Inc (CAI)$7.4B
Bausch + Lomb (BLCO)$5B
Amplifon S.p.A (AMFPF)$3.9B
BrightSpring Health Services (BTSG)$3.6B
Sotera Health (SHC)$3.1B
GeneDx Holdings (WGS)$3B
Surgery Partners (SGRY)$2.9B
Alignment Healthcare (ALHC)$2.7B
Concentras Parent (CON)$2.6B
Organon (OGN)$2.3B
Progyny (PGNY)$2B
Premier (PINC)$1.8B